Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BDC-4182 · 1 trial · 2 indications
Escalation period
Escalation period
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Escalating doses followed by backfill of selected doses |
| Dose Expansion | EXPERIMENTAL | Expansion at determined RP2D |
| Name | Type | Description |
|---|---|---|
| BDC-4182 | DRUG | Immune stimulating antibody conjugate (ISAC), consisting of an anti-claudin 18.2 monoclonal antibody conjugated to a TLR 7/8 dual agonist |
Key Inclusion Criteria: * Has disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1. * Subjects must have histologically/cytologically confirmed gastric or gastroesophageal cancer that is metastatic (Stage 4) or unresectable (Stage 3). * Subjects must have receiv...
BDC-4182 is an investigational small molecule being developed for the treatment of metastatic gastric cancer adenocarcinoma and gastroesophageal adenocarcinoma. It is currently being studied in a first-in-human Phase 1 clinical trial as a single agent in patients with these advanced cancers.
BDC-4182 targets claudin 18.2, a protein that is often expressed in gastric and gastroesophageal cancers. By targeting this protein, the drug aims to interfere with cancer cell growth and survival. It is being evaluated as a monotherapy in a Phase 1 clinical trial.
BDC-4182 is being developed by Bolt Biotherapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BOLT. The company is conducting a Phase 1 clinical trial to evaluate the drug as a single agent in advanced gastric and gastroesophageal cancer.
BDC-4182 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing Phase 1 trial is a first-in-human study designed to assess the safety, tolerability, and preliminary efficacy of BDC-4182 as a single agent.
BDC-4182 is being studied in a single active Phase 1 clinical trial with the identifier NCT06921837. The trial, titled "A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer," is currently recruiting participants in Australia, South Korea, and Taiwan.
BDC-4182 is a distinct investigational small molecule that targets claudin 18.2. It is being developed by Bolt Biotherapeutics and is not known to be the same as any other drug. Its unique mechanism and development program are being evaluated in a Phase 1 clinical trial.